Janoria Kumar G, Mitra Ashim K
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 5005 Rockhill Road, KPB, Kansas City, MO 64110-2499, USA.
Int J Pharm. 2007 Jun 29;338(1-2):133-41. doi: 10.1016/j.ijpharm.2007.01.038. Epub 2007 Feb 2.
The aim of this study is to investigate the roles of the lactide/glycolide ratio and prodrug derivatization on the in vitro release of ganciclovir and its lipophilic prodrug (GCV-monobutyrate) from PLGA microspheres for the treatment of cytomegalovirus (CMV) retinitis.
Two grades of PLGA, a higher lactide content PLGA 6535 [d,l-lactide:glycolide=65:35, MW 45,000-75,000Da] and lower lactide content PLGA 5050 [d,l-lactide:glycolide=50:50, MW 45,000-75,000Da] were employed to prepare GCV loaded microspheres. The effect of lipophilic prodrug derivatization was investigated by converting GCV to GCV-monobutyrate (GCVMB). Microspheres were prepared by the oil-in-oil (O/O) solvent evaporation method and characterized in vitro, by studying their surface/internal morphology, entrapment efficiency, particle size, drug release, true density and glass transition temperature. In vitro release data were analyzed by a model equation to estimate various parameters of the drug release curves.
The O/O solvent evaporation method generated a high drug payload of up to 91%. Higher entrapment efficiencies were observed in the case of hydrophilic drug (GCV) relative to the lipophilic prodrug (GCVMB). Loosely bound or surface adsorbed drug/prodrug molecules may have resulted in the very short period (about 6h) of the initial burst phase in all types of microspheres. GCV loaded microspheres utilized more time to release 50% (T(50) value) of entrapped drug than GCVMB microspheres. T(50) values estimated for GCVMB were shorter than those for GCV from microspheres with similar lactide/glycolide ratios. Lactide content in PLGA did not significantly alter GCVMB release relative to GCV release. The proposed model equation effectively estimated the drug release parameters (R(2)>0.98) with all drug/prodrug-PLGA combinations. SEM pictures have revealed that although both GCV and GCVMB microspheres were spherical but internal morphology was different, with former having uniform and dense whereas later have porous structures. Corroborating with internal morphologies, results revealed that true densities of GCV microspheres were relatively greater than corresponding GCVMB microspheres.
The proposed method of preparation yields higher efficiency of drug entrapment for the hydrophilic drug. Prodrug entrapment into microspheres could result in longer residence time at the site of administration due to multiple processes involved in drug release at infected tissue. These processes include release from microspheres and enzymatic conversion of the prodrug to parent drug.
本研究旨在探讨丙交酯/乙交酯比例和前药衍生化对更昔洛韦及其亲脂性前药(更昔洛韦单丁酸酯)从聚乳酸-羟基乙酸共聚物(PLGA)微球中的体外释放的影响,用于治疗巨细胞病毒(CMV)视网膜炎。
采用两种等级的PLGA,即丙交酯含量较高的PLGA 6535 [d,l-丙交酯:乙交酯=65:35,分子量45,000 - 75,000Da]和丙交酯含量较低的PLGA 5050 [d,l-丙交酯:乙交酯=50:50,分子量45,000 - 75,000Da]来制备载更昔洛韦微球。通过将更昔洛韦转化为更昔洛韦单丁酸酯(GCVMB)来研究亲脂性前药衍生化的影响。采用油包油(O/O)溶剂蒸发法制备微球,并通过研究其表面/内部形态、包封率、粒径、药物释放、真密度和玻璃化转变温度进行体外表征。通过模型方程分析体外释放数据以估计药物释放曲线的各种参数。
O/O溶剂蒸发法产生了高达91%的高药物载量。与亲脂性前药(GCVMB)相比,亲水性药物(更昔洛韦)的包封率更高。松散结合或表面吸附的药物/前药分子可能导致了所有类型微球中初始爆发期非常短(约6小时)。载更昔洛韦微球释放50%(T(50)值)包封药物所需的时间比GCVMB微球更长。对于具有相似丙交酯/乙交酯比例的微球,GCVMB的T(50)值比更昔洛韦的短。PLGA中的丙交酯含量相对于更昔洛韦的释放并没有显著改变GCVMB的释放。所提出的模型方程有效地估计了所有药物/前药 - PLGA组合的药物释放参数(R(2)>0.98)。扫描电子显微镜(SEM)图片显示,尽管更昔洛韦和GCVMB微球均为球形,但内部形态不同,前者具有均匀致密的结构,而后者具有多孔结构。与内部形态相符,结果表明更昔洛韦微球的真密度相对高于相应的GCVMB微球。
所提出的制备方法对亲水性药物产生了更高的药物包封效率。前药包封入微球可能由于在感染组织处药物释放涉及的多个过程而导致在给药部位的停留时间更长。这些过程包括从前药微球中释放以及前药酶促转化为母体药物。